author

Hamza Shad

Hamza is a senior economist at Carta, analyzing data on startups and private markets. He has been quoted in Bloomberg, WSJ Pro, CNBC, Business Insider, and more. Previously, Hamza conducted research on entrepreneurship in emerging markets at Endeavor. He is an alum of the University of Chicago and University of Oxford.
Hamza is a senior economist at Carta, analyzing data on startups and private markets. He has been quoted in Bloomberg,...

Latest from Hamza Shad

Fund Economics Report 2025
featured article
Fund Economics Report 2025
The details of how private funds operate have always remained behind the curtain. Now, Carta provides a never-before-seen glimpse at how VC and PE investors manage and operate their funds.
Ownership trends in private equity: 2024
Data & Research
September 2024
Ownership trends in private equity: 2024
Our second annual Ownership Trends in Private Equity report provides a status update on the progress private equity has made toward the commitment to expand employee ownership.
View
Carta Policy Insights: Decoding the Data | Emerging venture capital managers
Policy
September 2024
Carta Policy Insights: Decoding the Data | Emerging venture capital managers
Emerging managers are critical to expanding the innovation economy and driving U.S. competitiveness. Carta advocates for better policies to support them.
View
State of pre-seed: Q2 2024
Data & Research
August 2024
State of pre-seed: Q2 2024
Pre-seed investing continues to evolve. Carta's Q2 2024 report on pre-seed investing examines trends in financings at the earliest stage of the startup lifecycle.
View
State of Private Markets: Q2 2024
Featured
August 2024
State of Private Markets: Q2 2024
In Q2 2024, the venture ecosystem showed modest signs of improvement.
View
State of Startup Compensation, H1 2024
Data & Research
July 2024
State of Startup Compensation, H1 2024
Carta data shows that companies have become leaner and salary benchmarks have remained flat across much of the ecosystem.
View
VC funding in healthcare has been more resilient than other industries
Data & Research
June 2024
VC funding in healthcare has been more resilient than other industries
Health and biotech VC fundraising surged in the aftermath of the COVID-19 pandemic and has stood strong against market headwinds.
View